Wall Street analysts expect Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to post earnings per share (EPS) of $0.30 for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Supernus Pharmaceuticals’ earnings. The lowest EPS estimate is $0.21 and the highest is $0.44. Supernus Pharmaceuticals reported earnings of $0.44 per share in the same quarter last year, which would indicate a negative year over year growth rate of 31.8%. The firm is expected to report its next earnings report on Tuesday, February 26th.
On average, analysts expect that Supernus Pharmaceuticals will report full-year earnings of $1.87 per share for the current year, with EPS estimates ranging from $1.78 to $2.02. For the next financial year, analysts anticipate that the business will report earnings of $2.35 per share, with EPS estimates ranging from $2.10 to $2.55. Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Supernus Pharmaceuticals.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.43 by $0.09. The company had revenue of $102.99 million for the quarter, compared to analysts’ expectations of $100.75 million. Supernus Pharmaceuticals had a net margin of 25.89% and a return on equity of 30.30%. The firm’s revenue was up 28.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.29 earnings per share.
SUPN has been the topic of a number of analyst reports. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $44.00 price objective on shares of Supernus Pharmaceuticals in a report on Thursday, August 9th. Cantor Fitzgerald set a $57.00 price objective on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, November 7th. Mizuho initiated coverage on shares of Supernus Pharmaceuticals in a report on Monday, September 17th. They issued a “buy” rating and a $61.00 price objective on the stock. ValuEngine cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday. Finally, B. Riley dropped their price objective on shares of Supernus Pharmaceuticals from $68.00 to $65.00 and set a “buy” rating on the stock in a report on Monday, November 12th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $56.89.
Shares of SUPN stock traded down $5.47 during trading hours on Thursday, reaching $40.54. The stock had a trading volume of 2,278,263 shares, compared to its average volume of 706,231. The company has a quick ratio of 2.65, a current ratio of 2.82 and a debt-to-equity ratio of 0.77. Supernus Pharmaceuticals has a twelve month low of $34.90 and a twelve month high of $61.25. The stock has a market cap of $2.40 billion, a PE ratio of 32.17, a price-to-earnings-growth ratio of 1.45 and a beta of 0.93.
Hedge funds have recently added to or reduced their stakes in the stock. Glenmede Trust Co. NA increased its holdings in shares of Supernus Pharmaceuticals by 3.2% in the 2nd quarter. Glenmede Trust Co. NA now owns 652,806 shares of the specialty pharmaceutical company’s stock worth $39,070,000 after acquiring an additional 20,012 shares during the period. Janney Montgomery Scott LLC grew its position in Supernus Pharmaceuticals by 28.1% in the 3rd quarter. Janney Montgomery Scott LLC now owns 13,860 shares of the specialty pharmaceutical company’s stock valued at $698,000 after buying an additional 3,039 shares in the last quarter. Icon Advisers Inc. Co. bought a new position in Supernus Pharmaceuticals in the 3rd quarter valued at about $3,877,000. Oppenheimer Asset Management Inc. grew its position in Supernus Pharmaceuticals by 9.2% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 14,813 shares of the specialty pharmaceutical company’s stock valued at $746,000 after buying an additional 1,251 shares in the last quarter. Finally, Cynosure Advisors LLC grew its position in Supernus Pharmaceuticals by 55.0% in the 2nd quarter. Cynosure Advisors LLC now owns 8,260 shares of the specialty pharmaceutical company’s stock valued at $494,000 after buying an additional 2,930 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
Read More: Dividend Aristocrat Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.